Mark W. Womack
Chief Executive Officer at Selexis SA
Profile
Mark W.
Womack is currently the Chief Executive Officer at Selexis SA. Prior to this, he was the Chief Executive Officer at KBI Biopharma, Inc. from 2022 to 2023.
He also served as the Chief Executive Officer at Stelis Biopharma Ltd.
and as the Chief Business Officer at AGC Biologics, Inc.
Mark W. Womack active positions
Companies | Position | Start |
---|---|---|
Selexis SA
Selexis SA Miscellaneous Commercial ServicesCommercial Services Selexis SA provides research and development services in the field of mammalian cell lines. Its product SUREtechnology Platform improves the way cells are used in the discovery, development and manufacturing of recombinant proteins and drugs. The company was founded by Nicolas Mermod, Igor Edouard Fisch and Peter A. Pfister in 2001 and is headquartered in Plan-les-Ouates, Switzerland. | Chief Executive Officer | 02/05/2022 |
Former positions of Mark W. Womack
Companies | Position | End |
---|---|---|
KBI Biopharma, Inc.
KBI Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC. | Chief Executive Officer | 17/04/2023 |
Stelis Biopharma Ltd.
Stelis Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Stelis Biopharma Pvt Ltd. develops and manufactures pharmaceutical products. The company was founded in 2007 and is headquartered in Bangalore, India. | Chief Executive Officer | - |
AGC Biologics, Inc.
AGC Biologics, Inc. Pharmaceuticals: OtherHealth Technology AGC Biologics, Inc. develops therapeutic proteins for early clinical trials. The firm offers integrated cGMP manufacturing services using microbial fermentation and mammalian cell culture processes. The company was founded in 2007 and is headquartered in Bothell, WA. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
AGC Biologics, Inc.
AGC Biologics, Inc. Pharmaceuticals: OtherHealth Technology AGC Biologics, Inc. develops therapeutic proteins for early clinical trials. The firm offers integrated cGMP manufacturing services using microbial fermentation and mammalian cell culture processes. The company was founded in 2007 and is headquartered in Bothell, WA. | Health Technology |
Stelis Biopharma Ltd.
Stelis Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Stelis Biopharma Pvt Ltd. develops and manufactures pharmaceutical products. The company was founded in 2007 and is headquartered in Bangalore, India. | Health Technology |
KBI Biopharma, Inc.
KBI Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC. | Commercial Services |
Selexis SA
Selexis SA Miscellaneous Commercial ServicesCommercial Services Selexis SA provides research and development services in the field of mammalian cell lines. Its product SUREtechnology Platform improves the way cells are used in the discovery, development and manufacturing of recombinant proteins and drugs. The company was founded by Nicolas Mermod, Igor Edouard Fisch and Peter A. Pfister in 2001 and is headquartered in Plan-les-Ouates, Switzerland. | Commercial Services |
- Stock Market
- Insiders
- Mark W. Womack